Compare RELL & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | OBIO |
|---|---|---|
| Founded | 1947 | 2017 |
| Country | United States | United States |
| Employees | 429 | N/A |
| Industry | Electronic Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.2M | 253.9M |
| IPO Year | 2004 | 2020 |
| Metric | RELL | OBIO |
|---|---|---|
| Price | $17.71 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 246.9K | ★ 293.2K |
| Earning Date | 04-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $228,564,000.00 | $33,482,000.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $7.91 | $12.43 |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | 9.41 | ★ 1169.22 |
| 52 Week Low | $9.37 | $2.20 |
| 52 Week High | $23.15 | $5.78 |
| Indicator | RELL | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 60.70 |
| Support Level | $15.31 | $3.72 |
| Resistance Level | $19.40 | $5.42 |
| Average True Range (ATR) | 0.78 | 0.31 |
| MACD | -0.25 | 0.01 |
| Stochastic Oscillator | 36.97 | 56.01 |
Richardson Electronics Ltd is a world-wide manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions. It serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. Its products and services include design-in support, systems integration, prototype design and manufacturing, testing, logistics, etc. Its segments are Power and Microwave Technologies (PMT), Green Energy Solutions (GES), and Canvys. Majority of Sales is from PMT. Majority of sales is from North America.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.